Health-related quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer

Breast Cancer Research and Treatment

Volumn 145, Issue 1, 2014, Pages 155-164

  Taira, Naruto ^a   Iwata, Hiroji ^b   Hasegawa, Yoshie ^c   Sakai, Takehiko ^d   Higaki, Kenji ^e   Kihara, Kiyohiro ^f   Yamaguchi, Takuhiro ^g   Ohsumi, Shozo ^h   Shimozuma, Kojiro ⁱ   Ohashi, Yasuo ^f  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c Hirosaki City Hospital   (Japan)

^d CANCER INSTITUTE HOSPITAL   (Japan)

^e HIROSHIMA CITY HOSPITAL   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

ⁱ RITSUMEIKAN UNIVERSITY   (Japan)

Author keywords

Aromatase inhibitor; Breast cancer; HRQoL; Neoadjuvant endocrine therapy; Patient reported outcome

Indexed keywords

LETROZOLE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; NITRILE; TRIAZOLE DERIVATIVE;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISTRESS SYNDROME; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; SCORING SYSTEM; SURVIVAL RATE; AGED; BREAST NEOPLASMS; CLINICAL TRIAL; MENTAL STRESS; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROCEDURES; PSYCHOLOGY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NITRILES; POSTMENOPAUSE; QUALITY OF LIFE; QUESTIONNAIRES; STRESS, PSYCHOLOGICAL; TRIAZOLES;

EID: 84900513459     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2935-5     Document Type: Article

References (34)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771-784. doi: 10.1016/S0140-6736(11)60993-8
2. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509-518. doi: 10.1200/JCO.2009.23.1274
3. Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A (2004) Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 22:4261-4271
4. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A (2006) Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 100:273-284
5. Ohsumi S, Shimozuma K, Ohashi Y, Shinji M, Hozumi Y, Mukai H, Takatsuka Y, Aihara T (2011) Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03. Breast Cancer Res Treat 127:143-152. doi: 10.1007/s10549-011-1400-y
6. van Nes JG, Fontein DB, Hille ET, Voskuil DW, van Leeuwen FE, de Haes JC, Putter H, Seynaeve C, Nortier JW, van de Velde CJ (2012) Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study. Breast Cancer Res Treat 134:267-276. doi: 10.1007/s10549-012-2028-2
7. Fallowfield LJ, Bliss JM, Porter LS, Price MH, Snowdon CF, Jones SE, Coombes RC, Hall E (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2-3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24:910-917
8. Fallowfield LJ, Kilburn LS, Langridge C, Snowdon CF, Bliss JM, Coombes RC, Trial Steering Committee IES (2012) Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. Br J Cancer 106:1062-1067. doi: 10.1038/bjc.2012.43
9. Buijs C, de Vries EG, Mourits MJ, Willemse PH (2008) The influence of endocrine treatments for breast cancer on health-related quality of life. Cancer Treat Rev 34:640-655. doi: 10.1016/j.ctrv.2008.04.001
10. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667
11. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734
12. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF, Breast Cancer Intergroup of North America (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, estrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55-65. doi: 10.1016/S1470-2045(09)70314-6
13. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432-444. doi: 10.1016/S0140-6736(11)61625-5
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
15. Shimozuma K, Eguchi N. Development and clinical application of QOL measurement instruments for cancer patients: (I) Japanese versions of QOL questionnaires developed in North American or European countries and validation of reliability and validity of the FACT-B, a QOL questionnaire for breast cancer patients (in Japanese) http://www.jmari.med.or.jp/research/research.php?type= &mode=1&cno=&author=%B2%BC%BA%CA%B9%B8%C6%F3%CF%BA
16. Shimozuma K, Ohashi Y, Yoshimura K, Iha S, Saeki H, Kuroi K, Katsumata N, Okamoto T, Yamamoto Y, Tanaka K, Sonoo H (2000) Reliability and validity of the Japanese version of the Functional Assessment of Cancer Therapy-Breast (FACT-B) quality-of-life instrument; Women's Health Outcome Study (WHOS)-01. Qual Life Res 9:287 (abstract 1147)
17. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11:570-579
18. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G (1997) Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 15:974-986
19. Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D (1999) Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat 55:189-199
20. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361-370
21. Kugaya A, Akechi T, Okuyama T, Okamura H, Uchitomi Y (1998) Screening for psychological distress in Japanese cancer patients. Jpn J Clin Oncol 28:333-338
22. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EP (2008) Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 26:814-819. doi: 10.1200/JCO.2007.15.3510
23. Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA, Melnikova OA, Paltuev RM, Kletzel A, Berstein LM (2007) Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 110:244-254
24. Shannon C, Smith I (2003) Is there still a role for neoadjuvant therapy in breast cancer? Crit Rev Oncol Hematol 45:77-90
25. Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB (2005) Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23:6931-6940
26. Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, Sledge GW, Wood WC (2004) A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 57:898-910
27. Stearns V, Ullmer L, López JF, Smith Y, Isaacs C, Hayes D (2002) Hot flushes. Lancet 360:1851-1861
28. Taira N, Shimozuma K, Shiroiwa T, Ohsumi S, Kuroi K, Saji S, Saito M, Iha S, Watanabe T, Katsumata N (2011) Associations among baseline variables, treatment-related factors and health-related quality of life 2 years after breast cancer surgery. Breast Cancer Res Treat 128:735-747. doi: 10.1007/s10549-011-1631-y
29. Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, Meader N (2011) Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 12:160-174. doi: 10.1016/S1470-2045(11) 70002-X
30. Palmer SC, Taggi A, Demichele A, Coyne JC (2012) Is screening effective in detecting untreated psychiatric disorders among newly diagnosed breast cancer patients? Cancer 118:2735-2743. doi: 10.1002/cncr.26603
31. Bui QU, Ostir GV, Kuo YF, Freeman J, Goodwin JS (2005) Relationship of depression to patient satisfaction: findings from the barriers to breast cancer study. Breast Cancer Res Treat 89:23-28
32. Shimozuma K, Ganz PA, Petersen L, Hirji K (1999) Quality of life in the first year after breast cancer surgery: rehabilitation needs and patterns of recovery. Breast Cancer Res Treat 56:45-57
33. Al-Azri M, Al-Awisi H, Al-Moundhri M (2009) Coping with a diagnosis of breast cancer-literature review and implications for developing countries. Breast J 15:615-622. doi: 10.1111/j.1524-4741.2009.00812.x
34. Zainal NZ, Nik-Jaafar NR, Baharudin A, Sabki ZA, Ng CG (2013) Prevalence of depression in breast cancer survivors: a systematic review of observational studies. Asian Pac J Cancer Prev 14:2649-2656